Equities researchers at JMP Securities lifted their target price on shares of EXACT Sciences Corp. (NASDAQ:EXAS) from $10.00 to $17.00 in a research report issued on Wednesday, Stock Ratings Network reports. JMP Securities’ target price suggests a potential upside of 29.08% from the company’s current price.
A number of other analysts have also recently weighed in on EXAS. Analysts at Canaccord Genuity raised their price target on shares of EXACT Sciences Corp. from $14.00 to $17.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of EXACT Sciences Corp. in a research note to investors on Friday, July 12th. They now have a $18.00 price target on the stock, up previously from $14.00. Finally, analysts at Mizuho raised their price target on shares of EXACT Sciences Corp. from $13.00 to $18.00 in a research note to investors on Friday, June 7th. They now have a “buy” rating on the stock.
One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $15.50.
Shares of EXACT Sciences Corp. (NASDAQ: EXAS) traded down 2.30% during mid-day trading on Wednesday, hitting $13.17. EXACT Sciences Corp. has a 52 week low of $6.93 and a 52 week high of $14.70. The stock’s 50-day moving average is currently $13.32. The company’s market cap is $844.1 million.
EXACT Sciences Corp. (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, July 23rd. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.18) by $0.01. The company had revenue of $1.00 million for the quarter, compared to the consensus estimate of $1.02 million. During the same quarter in the prior year, the company posted ($0.26) earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. On average, analysts predict that EXACT Sciences Corp. will post $-0.73 earnings per share for the current fiscal year.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.